Chiltern And EPS INTERNATIONAL Enter Into A Global Partnership
Chiltern International Limited (Chiltern), a global Clinical Research Organization (CRO) that provides clinical development and staffing services in Europe, North America, Latin America and India recently announced that it had entered into a global partnership agreement with EPS International Co., Ltd. (EPS INTERNATIONAL), a wholly owned subsidiary of EPS Co., Ltd., a leading provider of a clinical development services in the Asian region.
Chiltern will provide services to EPS INTERNATIONAL from their network of offices in 23 countries throughout Europe, North America, South America and India. Similarly, EPS INTERNATIONAL will provide clinical development services for the Asian region from their offices in Japan, China, Singapore, Korea and Taiwan.
"We are pleased to have entered into a partnership with EPS INTERNATIONAL," said Glenn Kerkhof, CEO of Chiltern. "Asia is becoming an increasingly attractive market for clinical trial services and finding a partner with a meaningful presence and experience of conducting clinical trials throughout Southeast Asia is an important development for Chiltern. With EPS as our partner in this region we continue to focus on our mission to deliver expert, high quality, clinical development services around the world."
"We are delighted to have signed a partnership agreement with Chiltern," commented Dr. Tatsuhiko Ichiki, President & CEO of EPS INTERNATIONAL. "The core of our business has been in Asia and an increased demand for global trials outside of the region has made the timing for this partnership good. EPS and Chiltern have similar business philosophies and are both well regarded for the quality of their clinical services and personnel. With this partnership, we will be in a position to offer our sponsors an increased international reach while maintaining the high quality of services our sponsors have come to expect from EPS."
About Chiltern
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern employs more than 1200 people with 23 offices across the United States, Europe, Latin America and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Further information is available at www.chiltern.com
About EPS International
EPS International Co., Ltd. (EPS INTERNATIONAL), a wholly owned subsidiary of EPS Co., Ltd. (EPS), a public company on the First Section of Tokyo Stock Exchange, in Tokyo, Japan, commenced its operations in April 2007. EPS INTERNATIONAL is headquartered in Tokyo, Japan and provides clinical research and development platform services throughout the Asian region. EPS INTERNATIONAL is fully supported by a team of high caliber, diligent and dedicated clinical professionals having many years of experience managing large- and small-scale, global and local clinical trials, from first-in-man to post marketing study for new chemical entities, biologics and medical devices. Further information is available at www.chiltern.com.
SOURCE: Chiltern